Breaking News from ESCRS

Article

Breaking News from ESCRS

Saturday 12 September

Please click on any of the links below to read the full story

Breaking news story 1
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam non dolor nibh. Quisque laoreet porttitor justo, non vehicula lacus commodo viverra. Cras fringilla aliquam neque ac ornare.

Breaking news story 2
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam non dolor nibh. Quisque laoreet porttitor justo, non vehicula lacus commodo viverra. Cras fringilla aliquam neque ac ornare.

Breaking news story 3
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam non dolor nibh. Quisque laoreet porttitor justo, non vehicula lacus commodo viverra. Cras fringilla aliquam neque ac ornare.

Related Videos
Ana Neves, head of global marketing for ZEISS Meditec Ophthalmology
Fritz Hengerer, MD, PhD, Director, Eye Hospital at Bürgerhospital, Frankfurt, Germany
Dr Sheng Lim, professor of glaucoma studies at St Thomas' Hospital, London
Kasperi Kankare at the iCare booth at ESCRS
Scott D Barnes, MD, CMO of STAAR Surgical
Related Content

Treating anisometropic amblyopia with a dichoptic digital platform

September 28th 2023

Novel Therapies in Neovascular AMD and DME: Achieving Superior Anatomic Outcomes with Fewer Injections

June 29th 2023

US FDA approves RYZUMVI (Phentolamine Ophthalmic Solution) for the treatment of pharmacologically-induced mydriasis

September 27th 2023

Long-Term Efficacy and Durability of Latest Therapies in neovascular AMD and DMO

December 19th 2022

23rd annual EURETINA Congress: seeing eye to eye in Amsterdam

September 25th 2023

Study: Children with vision impairment have reduced quality of life

September 20th 2023

Treating anisometropic amblyopia with a dichoptic digital platform

September 28th 2023

Novel Therapies in Neovascular AMD and DME: Achieving Superior Anatomic Outcomes with Fewer Injections

June 29th 2023

US FDA approves RYZUMVI (Phentolamine Ophthalmic Solution) for the treatment of pharmacologically-induced mydriasis

September 27th 2023

Long-Term Efficacy and Durability of Latest Therapies in neovascular AMD and DMO

December 19th 2022

23rd annual EURETINA Congress: seeing eye to eye in Amsterdam

September 25th 2023

Study: Children with vision impairment have reduced quality of life

September 20th 2023

Treating anisometropic amblyopia with a dichoptic digital platform

September 28th 2023

Novel Therapies in Neovascular AMD and DME: Achieving Superior Anatomic Outcomes with Fewer Injections

June 29th 2023

US FDA approves RYZUMVI (Phentolamine Ophthalmic Solution) for the treatment of pharmacologically-induced mydriasis

September 27th 2023

Long-Term Efficacy and Durability of Latest Therapies in neovascular AMD and DMO

December 19th 2022

23rd annual EURETINA Congress: seeing eye to eye in Amsterdam

September 25th 2023

Study: Children with vision impairment have reduced quality of life

September 20th 2023
© 2023 MJH Life Sciences

All rights reserved.